• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OCGN

    Ocugen Inc.

    Subscribe to $OCGN
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: ocugen.com

    Peers

    $BXRX
    $CTIC
    $GOSS
    $ISEE
    $OTLK

    Recent Analyst Ratings for Ocugen Inc.

    DatePrice TargetRatingAnalyst
    10/15/2024$4.00Buy
    Maxim Group
    3/1/2023$3.50Neutral → Buy
    Chardan Capital Markets
    8/23/2022$5.00Buy
    Mizuho
    6/15/2022$8.00Buy
    ROTH Capital
    6/2/2022$4.50Overweight
    Cantor Fitzgerald
    2/28/2022$10.00 → $8.00Buy
    HC Wainwright & Co.
    7/26/2021Outperform
    Noble Capital Markets
    See more ratings

    Ocugen Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

      MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 1773288Webcast: Available on the events section of the Ocuge

      5/2/25 8:00:37 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

      MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt

      4/29/25 7:30:40 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

      MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy. "I look forward to sharing more on how Ocugen's modifier gene therapy platform can potentially change the treatment paradigm for major blindness diseases affecting hundreds of thousands to millions of patients by offering a one-time treatment for life," said Dr. Musunuri. "New techno

      4/8/25 8:02:14 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

      OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data following dosing of the first cohort in the dose-escalation portion of the Phase 1 study and approved continuation of dosing in the second cohort. OCU200 is a novel fusion protein consisting of two human

      3/18/25 8:02:09 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

      Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable safety and tolerability profile.Positive 2-year long-term data across multiple mutations of retinitis pigmentosa (RP) from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant (p=0.005) improvement in visual f

      3/5/25 7:02:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

      MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission has provided a positive opinion from the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) for OCU410 and OCU410ST Advanced Therapy Medicinal Product (ATMP) classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being developed for the treatment of patients with vision loss due to geographic atrophy (GA)—an advanced stage of dry age-related macular degeneration (dAMD)—and OCU410ST is being developed for Stargardt disease

      3/3/25 9:00:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

      MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission. The GARDian trial for OCU410ST demonstrated: A favorable safety and tolerability profile with no serious adverse events related to OCU410ST, including no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or chor

      2/27/25 8:46:50 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international calle

      2/21/25 8:00:45 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

      Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse events related to OCU410, including no cases of ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or choroidal neovascularization Subjects showed considerably slower lesion growth (44%) from baseline in treated eyes versus untreated fellow eyes at 9 months in follow-up data from the Phase 1 studyClinically meaningful 2-line (10-letter) improvement in visual function (LLVA) in treated eyes compared to untreated eyes was noted in the Phase 1 portion of the trialPreserva

      2/12/25 7:42:23 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

      MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Commission has provided a positive opinion from the European Medicines Agency's (EMA) Committee for Advanced Therapies (CAT) for OCU400 Advanced Therapy Medicinal Product (ATMP) classification. OCU400 is the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa (RP) indication. "Receiving ATMP classification is another significant milestone toward bringing OCU400 to the market in Europe," said Dr. Shankar Mu

      2/3/25 6:30:42 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Ocugen Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      12/2/24 4:15:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      11/26/24 4:50:10 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Ocugen Inc. SEC Filings

    See more
    • Ocugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      5/1/25 9:22:51 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Ocugen Inc.

      DEFA14A - Ocugen, Inc. (0001372299) (Filer)

      4/25/25 4:58:06 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Ocugen Inc.

      DEF 14A - Ocugen, Inc. (0001372299) (Filer)

      4/25/25 4:56:48 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Leadership Update

      8-K - Ocugen, Inc. (0001372299) (Filer)

      4/25/25 4:45:33 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      4/4/25 9:23:08 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Ocugen Inc.

      S-8 - Ocugen, Inc. (0001372299) (Filer)

      3/5/25 4:30:52 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Ocugen Inc.

      10-K - Ocugen, Inc. (0001372299) (Filer)

      3/5/25 9:42:59 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      3/5/25 6:59:40 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Ocugen, Inc. (0001372299) (Filer)

      3/3/25 8:43:25 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Ocugen Inc.

      EFFECT - Ocugen, Inc. (0001372299) (Filer)

      2/14/25 12:15:04 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Ocugen Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/12/24 4:59:47 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      11/4/24 1:43:41 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ocugen Inc.

      SC 13G - Ocugen, Inc. (0001372299) (Subject)

      10/16/24 12:41:30 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ocugen Inc. (Amendment)

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      1/22/24 12:42:58 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ocugen Inc. (Amendment)

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      7/7/23 4:35:54 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ocugen Inc. (Amendment)

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      2/10/23 10:58:27 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ocugen Inc. (Amendment)

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      4/11/22 2:13:44 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ocugen Inc.

      SC 13G - Ocugen, Inc. (0001372299) (Subject)

      2/11/22 10:02:46 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Ocugen Inc. (Amendment)

      SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

      2/10/22 8:28:05 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ocugen Inc.

      SC 13G - Ocugen, Inc. (0001372299) (Subject)

      2/4/22 4:26:08 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Ocugen Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Ramachandran Ramesh

      4 - Ocugen, Inc. (0001372299) (Issuer)

      1/6/25 5:02:56 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Upadhyay Arun covered exercise/tax liability with 41,633 shares, decreasing direct ownership by 12% to 306,197 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      1/6/25 5:02:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Musunuri Shankar covered exercise/tax liability with 177,146 shares, decreasing direct ownership by 9% to 1,832,723 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      1/6/25 5:01:44 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Qamar Huma

      4 - Ocugen, Inc. (0001372299) (Issuer)

      1/6/25 5:01:03 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      12/2/24 4:15:25 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      11/26/24 4:50:10 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Ramachandran Ramesh claimed ownership of 1,800 shares (SEC Form 3)

      3 - Ocugen, Inc. (0001372299) (Issuer)

      11/15/24 4:17:34 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Upadhyay Arun covered exercise/tax liability with 842 shares, decreasing direct ownership by 0.24% to 347,830 units (SEC Form 4)

      4 - Ocugen, Inc. (0001372299) (Issuer)

      9/26/24 4:27:41 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Whittington Marna C

      4 - Ocugen, Inc. (0001372299) (Issuer)

      7/2/24 4:10:34 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kompella Uday

      4 - Ocugen, Inc. (0001372299) (Issuer)

      7/2/24 4:10:13 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Ocugen Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ocugen with a new price target

      Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00

      10/15/24 8:07:55 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50

      3/1/23 9:04:17 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mizuho initiated coverage on Ocugen with a new price target

      Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00

      8/23/22 7:19:06 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ROTH Capital resumed coverage on Ocugen with a new price target

      ROTH Capital resumed coverage of Ocugen with a rating of Buy and set a new price target of $8.00

      6/15/22 9:42:52 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Ocugen with a new price target

      Cantor Fitzgerald initiated coverage of Ocugen with a rating of Overweight and set a new price target of $4.50

      6/2/22 7:15:11 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Ocugen with a new price target

      HC Wainwright & Co. reiterated coverage of Ocugen with a rating of Buy and set a new price target of $8.00 from $10.00 previously

      2/28/22 7:05:13 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Noble Capital Markets initiated coverage on Ocugen

      Noble Capital Markets initiated coverage of Ocugen with a rating of Outperform

      7/26/21 9:49:37 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen downgraded by ROTH Capital with a new price target

      ROTH Capital downgraded Ocugen from Buy to Neutral and set a new price target of $6.00 from $10.00 previously

      6/11/21 7:01:28 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Ocugen with a new price target

      HC Wainwright & Co. reiterated coverage of Ocugen with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      6/11/21 6:09:01 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Ocugen from Overweight to Neutral and set a new price target of $11.00 from $15.00 previously

      5/7/21 12:00:11 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Ocugen Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

      MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes

      9/9/24 6:30:12 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

      MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting

      5/28/24 7:02:39 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On April 1, 2024, Ocugen filed a Cur

      5/13/24 7:44:39 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

      MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO). "I'm very pleased to name Dr. Qamar as the CMO at Ocugen," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "This appointment recognizes her invaluable contributions to building a strong clinical team, overseeing a well-conducted Phase 1/2 gene therapy trial, and establishing relationships with leading medical and academic institutions and key o

      3/18/24 6:30:50 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

      MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer, has joined the Company's Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company's differentiated capabilities; and promoting access to the Company's the

      1/16/24 7:30:58 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • National Philanthropic Trust Welcomes Three Board Members

      Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees. "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "N

      1/3/24 9:30:00 AM ET
      $BANR
      $HLNE
      $OCGN
      Major Banks
      Finance
      Investment Managers
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer

      MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the appointment of Quan A. Vu to Chief Financial Officer & Chief Business Officer. "Quan has quickly become a tremendous asset for Ocugen and his comprehensive healthcare and financial expertise is providing valuable insight toward reaching our corporate goals," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "With Quan now overseeing both finance and business development, there will be a fully integr

      3/6/23 7:02:09 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Appoints Quan A. Vu as Chief Business Officer

      MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company's pipeline. "Expanding Ocugen's product portfolio and capabilities, in line with our long-term strategy, is imperative for 2023," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "We are very excited to have Quan join our leadership tea

      2/1/23 8:00:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer

      MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer. Arun Upadhyay, PhD, previously Senior Vice President, Research & Development, will now serve as the Company's Chief Scientific Officer, overseeing the development and manufacturing of Ocugen's clinical and commercial product portfolio and evaluating new technologies. "We are extremely pleased to have Dr. Hopkins driving our clinical programs as his expertise acro

      9/1/22 7:30:16 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

      MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022. "We're extremely pleased to welcome Dr. Marna Whittington to the Ocugen board," said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. "Her experiences will be exceedingly important to our growth strategy as we progress our modifier gene therapies and vaccine candidate. I also want to thank

      3/23/22 7:44:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Ocugen Inc. Financials

    Live finance-specific insights

    See more
    • Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

      MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 1773288Webcast: Available on the events section of the Ocuge

      5/2/25 8:00:37 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

      Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2. All subjects from multiple dose levels in Phase 2 to date demonstrated a very favorable safety and tolerability profile.Positive 2-year long-term data across multiple mutations of retinitis pigmentosa (RP) from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant (p=0.005) improvement in visual f

      3/5/25 7:02:00 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international calle

      2/21/25 8:00:45 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Provides Business Update with Third Quarter 2024 Financial Results

      Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trialNew data on Phase 1/2 clinical trials for OCU410, OCU410ST and OCU400 to be presented at upcoming Clinical Showcase MALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel

      11/8/24 6:45:51 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

      MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Friday, November 8, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID

      10/17/24 7:30:11 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

      MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 8, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 7453742We

      7/29/24 7:02:15 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Provides Business Update with First Quarter 2024 Financial Results

      All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets MALVERN, Pa., May 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today reported first quarter 2024 financial results along with a general business update. "We've experienced several important clinical and regulatory milestones since the beginning of 2024 that we believe

      5/14/24 8:00:25 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

      MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on May 20, 2024. The shares of Series C Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on May 22, 2024. The outstanding shares of Series C Preferred Stock will vote toget

      5/10/24 4:05:06 PM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

      MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 14, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 8699924Webcast

      5/3/24 7:30:05 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

      Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (RMAT) designation granted by FDA to OCU400 Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, tod

      4/2/24 8:00:39 AM ET
      $OCGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care